A trial update dated July 20, 2026 reports on a Phase 2 study that includes histrelin, an approved compound used in androgen deprivation therapy. The trial, registered as NCT06378866, is titled "Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer," known as the DIVINE Trial.
According to the listing, the trial is currently in Phase 2 and has a status of recruiting. The study evaluates stereotactic body radiation therapy combined with either immediate or delayed androgen receptor pathway inhibitor and androgen deprivation therapy, or salvage radiation therapy, for the treatment of prostate cancer. Histrelin is listed among the therapies used as part of androgen deprivation therapy in this trial design.
No results have been posted for this trial as of the event date. The current record reflects recruitment status only and does not include outcome data. Readers interested in additional details can consult the trial registration directly through the provided identifier, NCT06378866.
For more background on histrelin, including its approved uses and general profile, readers can consult the compound overview.